Digital comparator trial shows five-drug combo can keep ultra-high-risk myelomas in remission for longer
Combining five existing drugs can keep a highly aggressive type of bone marrow cancer at…
Browsing: bortezomib
EHA 2021: Daratumumab maintenance improves progression-free survival after autologous stem cell transplantation in multiple myeloma patients
Part 1 of the CASSIOPEIA phase-3 study compared the addition of daratumumab to bortezomib, thalidomide,…
Protected: Novel triplet therapy for newly diagnosed multiple myeloma patients now PBS listed
This content is password protected. To view it please enter your password below: Password:
Protected: Novel triplet therapy for newly diagnosed multiple myeloma patients now TGA approved
This content is password protected. To view it please enter your password below: Password:
Protected: New triplet therapy for patients with multiple myeloma now TGA approved
This content is password protected. To view it please enter your password below: Password:
EHA 2019: Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in relapsed / refractory multiple myleoma
Multiple myeloma is the second most common haematological cancer, and despite significant progress in the…
Multiple sclerosis drug could reduce painful side effects of common cancer treatment
Researchers from the Saint Louis University School of Medicine have discovered why many multiple myeloma…
Three drug combination extends survival for patients with multiple myeloma
For newly diagnosed patients with multiple myeloma who plan to delay autologous stem cell transplantation,…
Immunotherapy: Training the body to fight cancer
Balveen Kaur, The Ohio State University and Pravin Kaumaya, The Ohio State University The human…